In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 10, 1997, Pages 2165-2172

  Biavasco, Francesca ^a   Vignaroli, Carla ^a   Lupidi, Remo ^a   Manso, Esther ^b   Facinelli, Bruna ^a   Varaldo, Pietro E ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b General Hospital of Torrette   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; ORITAVANCIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CLOSTRIDIUM; CORYNEBACTERIUM; DRUG RESISTANCE; ENTEROCOCCUS; GEMELLA; LACTOCOCCUS; LISTERIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 0030820153     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.10.2165     Document Type: Article

References (43)

1. Arioli, V., and R. Pallanza. 1987. Teicoplanin-resistant coagulase-negative staphylococci. Lancet i:39.
2. Biavasco, F., E. Giovanetti, A. Miele, C. Vignaroli, B. Facinelli, and P. E. Varaldo. 1996. In vitro conjugative transfer of VanA vancomycin resistance between enterococci and listeriae of different species. Eur. J. Clin. Microbiol. Infect. Dis. 15:50-59.
3. Biavasco, F., E. Giovanetti, M. P. Muntanari, R. Lupidi, and P. E. Varaldo. 1991. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J. Antimicrob. Chemother. 27:71-79.
4. Biavasco, F., R. Lupidi, and P. E. Varaldo. 1992. In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873. Antimicrob. Agents Chemother. 36:331-338.
5. Biavasco, F., A. Miele, C. Vignaroli, E. Manso, R. Lupidi, and P. E. Varaldo. 1992. Genotypic characterization of a nosocomial outbreak of VanA Enterococcus faecalis. Microb. Drug Resist. 2:231-237.
6. Boylan, C. J., T. I. Nicas, D. A. Preston, D. L. Zeckner, B. J. Boyll, P. A. Raab, D. L. Mullen, N. J. Snyder, L. L. Zornes, R. E. Stratford, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson, and R. D. G. Cooper. 1995. Efficacy of semisynthetic glycopeptides active against vancomycin-resistant enterococci in a mouse infection model, abstr. F255, p. 157. In Program and abstracts of the 35th Interscicnce Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Centers for Disease Control and Prevention. 1993. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. Morbid. Mortal. Weekly Rep. 42:597-599.
8. Cohen, M. L. 1992. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257:1050-1055.
9. Cooper, G. L., and D. B. Given. 1986. Vancomycin: a comprehensive review of 30 years of clinical experience. Park Row Publishers, New York, N.Y.
10. Cooper, R. D. G., N. J. Snyder, M. J. Zweifel, M. A. Staszak, S. C. Wilkie, T. I. Nicas, D. L. Mullen, T. F. Butler, M. J. Rodriguez, B. E. Huff, and R. C. Thompson. 1996. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J. Antibiot. 49:575-581.
11. Dutka-Malen, S., B. Blaimont, G. Wauters, and P. Courvalin. 1994. Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob. Agents Chemother. 38:1675-1677.
12. Facinelli, B., E. Giovanetti, P. E. Varaldo, C. Casolari, and U. Fabio. 1991. Antibiotic resistance in foodborne listeria. Lancet 338:1272.
13. Fontana, R., M. Ligozzi, C. Pedrotti, E. M. Padovani, and G. Cornaglia. 1997. Vancomycin-resistant Bacillus circulans carrying the vanA gene responsible for vancomycin resistance in enterococci. Eur. J. Clin. Microbiol. Infect. Dis. 16:473-474.
14. French, G., Y. Abdulla, R. Heathcock, S. Poston, and J. Cameron. 1992. Vancomycin resistance in south London. Lancet 339:818-819.
15. Handwerger, S., M. J. Pucci, and A. Kolokathis. 1990. Vancomycin resistance is encoded on a pheromone response plasmid in Enterococcus faecium 228. Antimicrob. Agents Chemother. 34:358-360.
16. Leclercq, R., E. Derlot, J. Duval, and P. Courvalin. 1988. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 319:157-161.
17. Leclercq, R., E. Derlot, M. Weber, J. Duval, and P. Courvalin. 1989. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 33:10-15.
18. Lin, Y., R. E. Stratford, L. L. Zornes, W. L. Confer, V. Vasudevan, T. W. Jones, T. I. Nicas, D. A. Preston, C. J. Boylan, D. L. Zeckner, B. J. Boyll, P. A. Raab, N. J. Snyder, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson, and R. D. G. Cooper. 1995. Non-clinical pharmacokinetics of LY333328, a semisynthetic glycopeptide antibiotic active against vancomycin-resistant enterococci, abstr. F254, p. 157. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
19. Manso, E., G. De Sio, F. Biavasco, P. E. Varaldo, G. Sambo, and C. Maffei. 1993. Vancomycin-resistant enterococci. Lancet 342:615-617.
20. Moellering, R. C., Jr. 1991. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J. Antimicrob. Chemother. 28:1-12.
21. Murray, B. E. 1995. Editorial response: what can we do about vancomycin-resistant enterococci? Clin. Infect. Dis. 20:1134-1136.
22. Nagarajan, R. 1991. Antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob. Agents Chemother. 35:605-609.
23. Nagarajan, R. 1993. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J. Antibiot. 46:1181-1195.
24. National Committee for Clinical Laboratory Standards. 1992. Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline M26-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
25. National Committee for Clinical Laboratory Standards. 1993. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 3rd ed. Approved standard M11-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
26. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
27. Nicas, T. I., C. T. Cole, D. A. Preston, A. A. Schabel, and R. Nagarajan. 1989. Activity of glycopeptides against vancomycin-resistant gram-positive bacteria. Antimicrob. Agents Chemother. 33:1477-1481.
28. Nicas, T. I., D. H. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, R. A. Stratford, and R. D. G. Cooper. 1995. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Antimicrob. Agents Chemother. 39:2585-2587.
29. Nicas, T. I., D. H. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson, and R. D. G. Cooper. 1996. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 40:2194-2199.
30. Noble, W. C., Z. Virani, and R. G. A. Cree. 1992. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 93:195-198.
31. Poyart, C., C. Pierre, G. Quesne, B. Pron, P. Berche, and P. Trieu-Cuot. 1997. Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus boris. Antimicrob. Agents Chemother. 41:24-29.
32. Reynolds, P. E. 1985. Inhibitors of bacterial cell wall synthesis. Symp. Soc. Gen. Microbiol. 38:13-40.
33. Schwalbe, R. S., J. T. Stapleton, and P. H. Gilligan. 1987. Emergence of vancomycin resistance in coagulase-negative staphylococci. N. Engl. J. Med. 316:927-931.
34. Shlaes, D. M. 1992. Vancomycin-resistant bacteria. Infect. Control Hosp. Epidemiol. 13:193-194.
35. Shlaes, D. M., A. Bouvet, C. Devine, J. H. Shlaes, S. Al-Obeid, and R. Williamson. 1989. Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob. Agents Chemother. 33:198-203.
36. Spera, R. V., Jr., and B. F. Farber. 1992. Multiply-resistant Enterococcus faecium: the nosocomial pathogen of the 1990s. JAMA 268:2563-2564.
37. Uttley, A. H. C., C. H. Collins, J. Naidoo, and R. C. George. 1988. Vancomycin-resistant enterococci. Lancet i:57-58.
38. Uttley, A. H. C., R. C. George, J. Naidoo, N. Woodford, A. P. Johnson, C. H. Collins, D. Morrison, A. J. Gilfillan, L. E. Fitch, and J. Heptonstall. 1989. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol. Infect. 103:173-181.
39. Van der Auwera, P., N. Pensart, V. Korten, B. E. Murray, and R. Leclercq. 1996. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J. Infect. Dis. 173: 1129-1136.
40. Varaldo, P. E., E. Debbia, and G. C. Schito. 1983. In vitro activity of teichomycin and vancomycin alone and in combination with rifampin. Antimicrob. Agents Chemother. 23:402-406.
41. Venditti, M., F. Biavasco, P. E. Varaldo, A. Macchiarelli, L. De Biase, B. Marino, and P. Serra. 1993. Catheter-related endocarditis due to glycopeptide-resistant Enterococcus faecalis in a transplanted heart. Clin. Infect. Dis. 17:524-525.
42. Williams, A. H., and R. N. Grüneberg. 1988. Teicoplanin. J. Antimicrob. Chemother. 14:441-445.
43. Wilson, A. P. R., M. D. O'Hare, D. Felmingham, and R. N. Grüneberg. 1986. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet ii:973.